<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39331440</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1998-3689</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Indian journal of ophthalmology</Title><ISOAbbreviation>Indian J Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Targeted orbital intervention in the management of sino-orbital mucormycosis cases.</ArticleTitle><Pagination><StartPage>1488</StartPage><EndPage>1494</EndPage><MedlinePgn>1488-1494</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/IJO.IJO_18_24</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Many countries from South-East Asia reported an epidemic of sino-orbital mucormycosis (SOM), otherwise a rare disease, during the coronavirus disease 2019 pandemic. SOM, a potentially fatal disease, is typically treated with orbital exenteration and systemic antifungals after metabolic stabilization. There is no clear evidence of survival benefit of exenteration in the literature, and thus, there have been attempts at globe conserving treatments like orbital infusion after limited debridement and intraorbital injections with Amphotericin B (IOAB).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a prospective comparative interventional study at a tertiary eye care hospital to evaluate treatment outcomes with the use of adjunctive IOAB in cases of SOM with mild to moderate orbital disease.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-six patients of SOM with mild to moderate orbital disease were recruited in the study. In the intervention group, 23/26 (885%) eyes had stable orbital disease at the end of treatment (4-6 weeks). No deterioration in visual acuity was noted as a result of treatment. In 8/26 (30.77%) patients, inflammation was noted as a side effect of IOAB requiring temporary discontinuation of injections. The mean follow-up for cases was 14.2 months (range 12-15 months). 1/23 (4.35%) patients had relapse of orbital disease at 3 months. Twenty-one patients are alive on last follow-up. Of the patients who refused treatment (controls), 2/9 (22.22%) patients relapsed. One of these patients with relapse underwent exenteration, while the other was managed with IOAB. At a follow-up of 14 months (range 12-15 months), eight patients are alive. On evaluating the ocular parameters in salvaged eyes, improvement in extraocular movements was noted in 75-80% cases. The degree of proptosis and resistance to retropulsion did not change significantly.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In the current study, an improvement in the globe salvage rates was noted in cases of SOM with mild to moderate orbital disease treated with adjunctive IOAB as compared to controls at a mean follow-up of 14 months, although it did not achieve statistical significance. The study supports the inclusion of IOAB in routine management of mild to moderate orbital disease.</AbstractText><CopyrightInformation>Copyright © 2024 Copyright: © 2024 Indian Journal of Ophthalmology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meel</LastName><ForeName>Rachna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bajaj</LastName><ForeName>Mandeep S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pushker</LastName><ForeName>Neelam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Sahil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tyagi</LastName><ForeName>Parag</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thakkar</LastName><ForeName>Alok</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of ENT, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of ENT, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pachaury</LastName><ForeName>Shuchita S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of ENT, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wig</LastName><ForeName>Navneet</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Ophthalmol</MedlineTA><NlmUniqueID>0405376</NlmUniqueID><ISSNLinking>0301-4738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7XU7A7DROE</RegistryNumber><NameOfSubstance UI="D000666">Amphotericin B</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009091" MajorTopicYN="Y">Mucormycosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015821" MajorTopicYN="Y">Eye Infections, Fungal</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009916" MajorTopicYN="Y">Orbital Diseases</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000935" MajorTopicYN="Y">Antifungal Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000666" MajorTopicYN="Y">Amphotericin B</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003646" MajorTopicYN="N">Debridement</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009915" MajorTopicYN="N">Orbit</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>11</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39331440</ArticleId><ArticleId IdType="doi">10.4103/IJO.IJO_18_24</ArticleId><ArticleId IdType="pii">02223307-202472100-00020</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kamath S, Kumar M, Sarkar N, Ahmed T, Sunder A. Study of profile of mucormycosis during the second wave of COVID-19 in a tertiary care hospital. Cureus 2022;14:e21054.</Citation></Reference><Reference><Citation>Fouad YA, Abdelaziz TT, Askoura A, Saleh MI, Mahmoud MS, Ashour DM, et al. Spike in rhino-orbital-cerebral mucormycosis cases presenting to a tertiary care center during the COVID-19 pandemic. Front Med (Lausanne) 2021;8:645270.</Citation></Reference><Reference><Citation>Saluja G, Bhari A, Pushker N, Agrawal S, Meel R, Thakar A, et al. Experience on rhino-orbital mucormycosis from a tertiary care hospital in the first wave of COVID-19: An Indian perspective. Med J Armed Forces India 2022;79:S94–101.</Citation></Reference><Reference><Citation>Kalin-Hajdu E, Hirabayashi KE, Vagefi MR, Kersten RC. Invasive fungal sinusitis: Treatment of the orbit. Curr Opin Ophthalmol 2017;28:522–33.</Citation></Reference><Reference><Citation>Kohn R, Hepler R. Management of limited rhino-orbital mucormycosis without exenteration. Ophthalmology 1985;92:1440–4.</Citation></Reference><Reference><Citation>Pelton RW, Peterson EA, Patel BC, Davis K. Successful treatment of rhinoorbital mucormycosis without exenteration: The use of multiple treatment modalities. Ophthal Plast Reconstr Surg 2001;17:62–6.</Citation></Reference><Reference><Citation>Luna JD, Ponssa XS, Rodriguez SD, Luna NC, Juárez CP. Intraconal amphotericin B for the treatment of rhino-orbital mucormycosis. Ophthalmic Surg Lasers 1996;27:706–8.</Citation></Reference><Reference><Citation>Kahana A, Lucarelli MJ. Use of radiopaque intraorbital catheter in the treatment of sino-orbito-cranial mucormycosis. Arch Ophthalmol 2007;125:1714–5.</Citation></Reference><Reference><Citation>Seiff SR, Choo PH, Carter SR. Role of local amphotericin B therapy for sinoorbital fungal infections. Ophthal Plast Reconstr Surg 1999;15:28–31.</Citation></Reference><Reference><Citation>Harris GJ, Will BR. Orbital aspergillosis. Conservative debridement and local amphotericin irrigation. Ophthal Plast Reconstr Surg 1989;5:207–11.</Citation></Reference><Reference><Citation>Joos ZP, Patel BC. Intraorbital irrigation of amphotericin B in the treatment of rhino-orbital mucormycosis. Ophthal Plast Reconstr Surg 2017;33:e13–6.</Citation></Reference><Reference><Citation>Saedi B, Sadeghi M, Seilani P. Endoscopic management of rhinocerebral mucormycosis with topical and intravenous amphotericin B. J Laryngol Otol 2011;125:807–10.</Citation></Reference><Reference><Citation>Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel) 2019;5:26.</Citation></Reference><Reference><Citation>Hargrove RN, Wesley RE, Klippenstein KA, Fleming JC, Haik BG. Indications for orbital exenteration in mucormycosis. Ophthal Plast Reconstr Surg 2006;22:286–91.</Citation></Reference><Reference><Citation>Turner JH, Soudry E, Nayak JV, Hwang PH. Survival outcomes in acute invasive fungal sinusitis: A systematic review and quantitative synthesis of published evidence. Laryngoscope 2013;123:1112–8.</Citation></Reference><Reference><Citation>Dhiwakar M, Thakar A, Bahadur S. Invasive sino-orbital aspergillosis: Surgical decisions and dilemmas. J Laryngol Otol 2003;117:280–5.</Citation></Reference><Reference><Citation>Mody KH, Ali MJ, Vemuganti GK, Nalamada S, Naik MN, Honavar SG. Orbital aspergillosis in immunocompetent patients. Br J Ophthalmol 2014;98:1379–84.</Citation></Reference><Reference><Citation>Pushker N, Meel R, Kashyap S, Bajaj MS, Sen S. Invasive aspergillosis of orbit in immunocompetent patients: Treatment and outcome. Ophthalmology 2011;118:1886–91.</Citation></Reference><Reference><Citation>Sivak-Callcott JA, Livesley N, Nugent RA, Rasmussen SL, Saeed P, Rootman J. Localised invasive sino-orbital aspergillosis: Characteristic features. Br J Ophthalmol 2004;88:681–7.</Citation></Reference><Reference><Citation>Clancy CJ, Nguyen MH. Invasive sinus aspergillosis in apparently immunocompetent hosts. J Infect 1998;37:229–40.</Citation></Reference><Reference><Citation>Aggarwal E, Mulay K, Menon V, Sundar G, Honavar SG, Sharma M. Isolated orbital aspergillosis in immunocompetent patients: A multicenter study. Am J Ophthalmol 2016;165:125–32.</Citation></Reference><Reference><Citation>Singh V, Sharma B, Sen R, Agrawal S, Bhagol A, Bali R. Rhinocerebral mucormycosis: A diagnostic challenge and therapeutic dilemma in immunocompetent host. J Oral Maxillofac Surg 2012;70:1369–75.</Citation></Reference><Reference><Citation>Zuo Q, Dong L, Mu W, Zhou L, Hu T, Zhang H. Trichosporon asahii infection after total knee arthroplasty: A case report and review of the literature. Can J Infect Dis Med Microbiol 2015;26:47–51.</Citation></Reference><Reference><Citation>Kfoury AG, Smith JC, Farhoud HH, Terreros DA, Stringham JC, Taylor DO, et al. Adjuvant intrapleural amphotericin B therapy for pulmonary mucormycosis in a cardiac allograft recipient. Clin Transplant 1997;11:608–12.</Citation></Reference><Reference><Citation>Hirabayashi KE, Kalin-Hajdu E, Brodie FL, Kersten RC, Russell MS, Vagefi MR. Retrobulbar injection of amphotericin B for orbital mucormycosis. Ophthal Plast Reconstr Surg 2017;33:e94–7.</Citation></Reference><Reference><Citation>Ashraf DC, Idowu OO, Hirabayashi KE, Kalin-Hajdu E, Grob SR, Winn BJ, et al. Outcomes of a modified treatment ladder algorithm using retrobulbar amphotericin B for invasive fungal rhino-orbital sinusitis. Am J Ophthalmol 2022;237:299–309.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>